Xylitol for C. diff reduction in IBD patients
Part of Digestive system, Infections clinical trials.
This trial tests if xylitol, a natural sugar substitute, can reduce the amount of C. difficile bacteria in the gut of people with inflammatory bowel disease (IBD) who are in remission or have mild symptoms. If successful, it might help prevent future C. diff infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with Crohn's disease, ulcerative colitis, or indeterminate colitis
- Your IBD is not active or only mildly active (low symptom scores)
- You are going for a routine colonoscopy or clinic visit
- You have not had your colon removed or any prior colon surgery (except appendix removal)
- You are not taking antibiotics regularly and can swallow capsules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether xylitol can help “decolonize” (reduce colonization of) C. difficile germs in people with inflammatory bowel disease (IBD). It may help lower the chance of C. diff becoming a problem, but it is mainly a safety/timing early study.
This study compares two medicines, fidaxomicin and vancomycin, to see which one is better at preventing C. diff infection in people with inflammatory bowel disease who are having a colonoscopy.
This trial tests whether adding a bile acid supplement (ursodeoxycholic acid) to standard antibiotics can help prevent a repeat C. diff infection. It is for people who have already had a C. diff infection and have at least one factor that increases their risk of it coming back.
This study tests if a freeze-dried fecal transplant (FMT) can help people with difficult-to-treat diarrhea caused by IBS-D or recurring C. diff infections. It's a way to restore healthy gut bacteria and may reduce symptoms.
This trial tests a new treatment called CMTS0929 for people with C. diff infection. It aims to see if the treatment can help clear the infection and improve symptoms.
This study tests a new antibody (AZD5148) to prevent C. diff infection from coming back. If you have a current C. diff infection and are being treated with antibiotics, you may be able to join.
Hear when a new Clostridioides Difficile Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.